4//SEC Filing
Revance Therapeutics, Inc. 4
Accession 0001209191-14-009043
CIK 0001479290operating
Filed
Feb 10, 7:00 PM ET
Accepted
Feb 11, 2:55 PM ET
Size
43.3 KB
Accession
0001209191-14-009043
Insider Transaction Report
Form 4
Glasheen James Walter
Director
Transactions
- Conversion
Common Stock
2014-02-11+16,703→ 16,703 total(indirect: by Technology Partners Affiliates VII, L.P.) - Conversion
Common Stock
2014-02-11+34,427→ 657,075 total(indirect: by Technology Partners Fund VII, L.P.) - Conversion
Series E-1 Convertible Preferred Stock
2014-02-11−5,231→ 0 total(indirect: by Technology Partners Affiliates VII, L.P.)→ Common Stock (5,231 underlying) - Conversion
Series E-1 Convertible Preferred Stock
2014-02-11−81,959→ 0 total(indirect: by Technology Partners Fund VII, L.P.)→ Common Stock (81,959 underlying) - Conversion
Series E-2 Convertible Preferred Stock
2014-02-11−4,125→ 0 total(indirect: by Technology Partners Affiliates VII, L.P.)→ Common Stock (4,125 underlying) - Conversion
Series E-2 Convertible Preferred Stock
2014-02-11−73,275→ 0 total(indirect: by Technology Partners Fund VII, L.P.)→ Common Stock (73,275 underlying) - Conversion
Series E-3 Convertible Preferred Stock
2014-02-11−4,546→ 0 total(indirect: by Technology Partners Affiliates VII, L.P.)→ Common Stock (4,546 underlying) - Conversion
Series E-3 Convertible Preferred Stock
2014-02-11−74,665→ 0 total(indirect: by Technology Partners Fund VII, L.P.)→ Common Stock (74,665 underlying) - Conversion
Series E-4 Convertible Preferred Stock
2014-02-11−2,801→ 0 total(indirect: by Technology Partners Affiliates VII, L.P.)→ Common Stock (2,801 underlying) - Conversion
Series E-4 Convertible Preferred Stock
2014-02-11−303,563→ 0 total(indirect: by Technology Partners Fund VII, L.P.)→ Common Stock (303,563 underlying) - Exercise of In-Money
Common Stock
2014-02-11+149→ 16,852 total(indirect: by Technology Partners Affiliates VII, L.P.) - Conversion
Common Stock
2014-02-11+622,648→ 622,648 total(indirect: by Technology Partners Fund VII, L.P.) - Exercise of In-Money
Common Stock
2014-02-11+52,087→ 709,162 total(indirect: by Technology Partners Fund VII, L.P.) - Conversion
Series E-5 Convertible Preferred Stock
2014-02-11−89,186→ 0 total(indirect: by Technology Partners Fund VII, L.P.)→ Common Stock (89,186 underlying) - Conversion
Convertible Promissory Notes
2014-02-11−34,427→ 0 total(indirect: by Technology Partners Fund VII, L.P.)→ Common Stock (34,427 underlying) - Exercise of In-Money
Warrant to Purchase Common Stock
2014-02-11−52,087→ 0 total(indirect: by Technology Partners Fund VII, L.P.)→ Common Stock (52,087 underlying) - Exercise of In-Money
Warrant to Purchase Common Stock
2014-02-11−149→ 0 total(indirect: by Technology Partners Affiliates VII, L.P.)→ Common Stock (149 underlying)
Footnotes (9)
- [F1]Issued upon conversion of Series E-1, E-2, E-3 and E-4 Preferred Stock upon closing of the Issuer's initial public offering.
- [F2]Each share of the Issuer's Series E-1, Series E-2, Series E-3, Series E-4 and Series E-5 Preferred Stock automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and has no expiration date.
- [F3]The shares are held by Technology Partners Affiliates VII, L.P. ("TPA"). TP Management VII, L.L.C., the general partner of TPA, may be deemed to have sole power to vote and sole power to dispose of shares directly owned by TPA. James Glasheen, one of the Issuer's directors, is a managing member of TP Management VII, L.L.C. and may be deemed to have shared voting power and shared power to dispose of the shares held by TPA.
- [F4]Issued upon closing of the Issuer's initial public offering pursuant to automatic net exercise of warrants to purchase common stock at an exercise price of $0.15 per share.
- [F5]Issued upon conversion of Series E-1, E-2, E-3, E-4 and E-5 Preferred Stock upon closing of the Issuer's initial public offering.
- [F6]The shares are held by Technology Partners Fund VII, L.P. ("TPF"). TP Management VII, L.L.C., the general partner of TPF, may be deemed to have sole power to vote and sole power to dispose of shares directly owned by TPF. James Glasheen, one of the Issuer's directors, is a managing member of TP Management VII, L.L.C. and may be deemed to have shared voting power and shared power to dispose of the shares held by TPF.
- [F7]Convertible Promissory Note in the aggregate principal amount of $500,000.00 was issued on December 6, 2013 by the Issuer pursuant to a Note and Warrant Purchase Agreement dated October 8, 2013, as amended. The principal amount of $500,000.00 plus interest accrued through October 7, 2014, at the rate of 12% per annum converted automatically upon the closing of the Issuer's initial public offering into shares of Common Stock at a conversion price that equals to 100% of the per share price of the Common Stock sold in the Issuer's initial public offering.
- [F8]Automatically net exercised into shares of the Issuer's Common Stock at an exercise price of $0.15 per share.
- [F9]Includes certain warrant to purchase capital stock of the Issuer issued on December 6, 2013 by the Issuer pursuant to a Note and Warrant Purchase Agreement dated October 8, 2013, as amended. The warrant shares were automatically net exercised into Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a per share exercise price of $0.15 per share on a post-split basis.
Documents
Issuer
Revance Therapeutics, Inc.
CIK 0001479290
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001479290
Filing Metadata
- Form type
- 4
- Filed
- Feb 10, 7:00 PM ET
- Accepted
- Feb 11, 2:55 PM ET
- Size
- 43.3 KB